Active Biotech AB (publ)

DB:BTPC Stock Report

Market Cap: €13.1m

Active Biotech Management

Management criteria checks 4/4

Active Biotech's CEO is Helen Tuvesson, appointed in Jul 2017, has a tenure of 7.5 years. total yearly compensation is SEK4.05M, comprised of 56% salary and 44% bonuses, including company stock and options. directly owns 0.031% of the company’s shares, worth €4.10K. The average tenure of the management team and the board of directors is 7.5 years and 5.7 years respectively.

Key information

Helen Tuvesson

Chief executive officer

SEK 4.0m

Total compensation

CEO salary percentage56.0%
CEO tenure7.5yrs
CEO ownership0.03%
Management average tenure7.5yrs
Board average tenure5.7yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Helen Tuvesson's remuneration changed compared to Active Biotech's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-SEK 42m

Jun 30 2024n/an/a

-SEK 44m

Mar 31 2024n/an/a

-SEK 45m

Dec 31 2023SEK 4mSEK 2m

-SEK 46m

Sep 30 2023n/an/a

-SEK 48m

Jun 30 2023n/an/a

-SEK 51m

Mar 31 2023n/an/a

-SEK 54m

Dec 31 2022SEK 4mSEK 2m

-SEK 58m

Sep 30 2022n/an/a

-SEK 60m

Jun 30 2022n/an/a

-SEK 57m

Mar 31 2022n/an/a

-SEK 56m

Dec 31 2021SEK 4mSEK 2m

-SEK 50m

Sep 30 2021n/an/a

-SEK 38m

Jun 30 2021n/an/a

-SEK 35m

Mar 31 2021n/an/a

-SEK 32m

Dec 31 2020SEK 3mSEK 2m

-SEK 32m

Sep 30 2020n/an/a

-SEK 39m

Jun 30 2020n/an/a

-SEK 40m

Mar 31 2020n/an/a

-SEK 36m

Dec 31 2019SEK 3mSEK 2m

-SEK 34m

Sep 30 2019n/an/a

-SEK 32m

Jun 30 2019n/an/a

-SEK 31m

Mar 31 2019n/an/a

-SEK 35m

Dec 31 2018SEK 3mSEK 1m

-SEK 37m

Compensation vs Market: Helen's total compensation ($USD364.30K) is about average for companies of similar size in the German market ($USD462.70K).

Compensation vs Earnings: Helen's compensation has been consistent with company performance over the past year.

CEO

Helen Tuvesson (62 yo)

7.5yrs

Tenure

SEK 4,045,000

Compensation

Ms. Helen Tuvesson, Ph.D. is President of Active Biotech AB and its Chief Executive Officer since 2017. She serves as Independent Director at Mendus AB (publ) (formerly known as Immunicum AB (publ)) since...

Leadership Team

NamePositionTenureCompensationOwnership
Helen Tuvesson
President & CEO7.5yrsSEK 4.05m0.031%
€ 4.1k
Hans Kolam
Chief Financial Officer25yrsno data0.023%
€ 3.1k
Erik Vahtola
Chief Medical Officer3yrsno data0.011%
€ 1.5k

7.5yrs

Average Tenure

62yo

Average Age

Experienced Management: BTPC's management team is seasoned and experienced (7.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Peter Thelin
Independent Director13.7yrsSEK 206.00kno data
Uli Hacksell
Independent Director5.7yrsSEK 202.00k0.0017%
€ 223.6
Michael Shalmi
Independent Chairman of the Board5.7yrsSEK 524.00k0.049%
€ 6.4k
Axel Glasmacher
Independent Director4.7yrsSEK 203.00k0.044%
€ 5.7k
Aleksandar Danilovski
Independent Director4.7yrsSEK 207.00k0.015%
€ 2.0k

5.7yrs

Average Tenure

64yo

Average Age

Experienced Board: BTPC's board of directors are considered experienced (5.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/05 19:04
End of Day Share Price 2025/01/03 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Active Biotech AB (publ) is covered by 13 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Morten LarsenABG Sundal Collier
Stefan WaldenlindCarnegie Investment Bank AB
Thomas BowersDanske Bank